For KRAS G12C mutant NSCLC patients who have previously received chemotherapy or immune checkpoint inhibitors, the use of Sotorasib in the CodeBreakK 200 study showed significant survival benefits compared to standard treatment (Docetaxel), with median PFS of 4.5 months and 5.6 months, respectively (p=0.0017) (44). Here, KRAS is linked to non-small cell lung carcinoma.